Management of recurrent acute lymphoblastic leukemia with T-cell engagement: CAR T, BiTEs, and beyond Journal Article


Author: Park, J.
Article Title: Management of recurrent acute lymphoblastic leukemia with T-cell engagement: CAR T, BiTEs, and beyond
Abstract: Immunotherapies targeting CD19 (blinatumomab) and CD22 (inotuzumab ozogamicin) have demonstrated higher complete response rates and improved survival compared with chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL), and are now standard of care in the relapsed setting. However, most adult patients still die of ALL despite these therapies, with or without hematopoietic stem cell transplant. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Jae Park summarized clinical data from key trials of novel immunotherapies in ALL and reviewed evidence-based treatment approaches for adults with relapsed/refractory B-cell ALL.
Keywords: therapy; adults; blinatumomab
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 17
Issue: 11.5
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2019-11-01
Start Page: 1448
End Page: 1450
Language: English
ACCESSION: WOS:000499644200013
DOI: 10.6004/jnccn.2019.5030
PROVIDER: wos
PUBMED: 31766014
Notes: Source: Wos
Altmetric
Citation Impact
MSK Authors
  1. Jae Hong Park
    178 Park